Loading…
Immatics N.V. is projected to rise to $10.86 by 2027, a +25% move from its current price of $8.66. IMTX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $8.44 | $8.66 | $8.89 | +0.04% |
| Aug 3 | $8.36 | $8.67 | $8.99 | +0.08% |
| Aug 4 | $8.29 | $8.67 | $9.07 | +0.12% |
| Aug 5 | $8.24 | $8.67 | $9.13 | +0.16% |
| Aug 6 | $8.19 | $8.68 | $9.19 | +0.20% |
| Aug 7 | $8.15 | $8.68 | $9.25 | +0.24% |
| Aug 8 | $8.11 | $8.68 | $9.30 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.11 | $8.68 | $9.30 | +0.28% |
| Week 2 | $7.90 | $8.71 | $9.59 | +0.56% |
| Week 3 | $7.75 | $8.73 | $9.83 | +0.83% |
| Week 4 | $7.63 | $8.76 | $10.04 | +1.11% |
| Week 5 | $7.53 | $8.78 | $10.23 | +1.39% |
| Week 6 | $7.44 | $8.81 | $10.41 | +1.68% |
| Week 7 | $7.37 | $8.83 | $10.58 | +1.96% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Immatics N.V. is a clinical-stage biopharmaceutical company focused on research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. Its work targets solid tumors using two distinct modalities: adoptive cell therapies and antibody-like TCR bispecifics.
The company’s pipeline includes Anzu-cel (IMA203), described as a one-time infusion PRAME cell therapy in Phase 2, along with IMA203CD8 in Phase 1, IMA204 targeting the tumor stroma in Phase 1, and Anzu-cel combined with Moderna’s PRAME cell therapy enhancer (mRNA-4203) also in Phase 1. Immatics also develops TCR Bispecifics such as IMA401 and IMA402 in Phase 1a. The company maintains strategic collaborations with MD Anderson Cancer Center, Celgene Corporation, and Genmab A/S to develop multiple T cell and TCR-based therapies.
Immatics N.V. is headquartered in Tübingen, Germany.
Immatics N.V. (IMTX) is a clinical-stage biopharmaceutical company focused on cancer therapies, with a current price of $9.17 and a market capitalization of $1.25B. It is ranked 2289 by market cap among publicly traded assets. The stock’s current level sits near its 50-day and 200-day moving averages, reflecting the near-term price environment.
A major floor 12.8% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.3% away) — a key level to hold.
The nearest ceiling, 18.5% above — a clean break opens room to run.
A major ceiling 34.2% above — clearing it would confirm fresh momentum.
Key IMTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IMTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.84 | Sell | $8.91 | Sell |
| MA 10 | $9.04 | Sell | $9.04 | Sell |
| MA 20 | $9.37 | Sell | $9.26 | Sell |
| MA 50 | $9.80 | Sell | $9.67 | Sell |
| MA 100 | $10.17 | Sell | $9.87 | Sell |
| MA 200 | $10.09 | Sell | $9.59 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.74 | Neutral |
| Stoch RSI (14) | 34.51 | Neutral |
| CCI (20) | -136.17 | Sell |
| Williams %R (14) | -96.88 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -8.55 | Sell |
| Bollinger %B (20,2) | 0.10 | Neutral |
| Stochastic %K (14) | 3.12 | Buy |
| TRIX (15) | -0.34 | Sell |
| Awesome (5,34) | -0.65 | Sell |
| Ultimate (7,14,28) | 38.44 | Neutral |
| Momentum (10) | -0.93 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 8.86 | Sell |
| ADX (14) | 15.25 | Neutral |
| ATR (14) | 0.25 | Info |
The 30-day technical picture shows a bearish tilt with RSI(14) at 40, suggesting modest downward momentum. The stock’s near-term trend sits between moving averages, with the SMA50 at $10.09 and the SMA200 at $10.13 as reference levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.57 | $8.66 | $11.24 | 0% | Neutral | |
| $8.70 | $10.86 | $14.31 | +25% | Bullish | |
| $9.56 | $12.25 | $16.73 | +41% | Bullish | |
| $10.26 | $13.44 | $18.88 | +55% | Bullish | |
| $10.27 | $13.72 | $19.72 | +58% | Bullish | |
| $10.36 | $14.08 | $20.66 | +63% | Bullish | |
| $11.05 | $15.27 | $22.82 | +76% | Bullish | |
| $12.66 | $17.76 | $26.98 | +105% | Bullish | |
| $14.93 | $21.26 | $32.80 | +145% | Bullish | |
| $15.00 | $21.65 | $33.88 | +150% | Bullish | |
| $21.14 | $32.49 | $53.97 | +275% | Bullish | |
| $30.25 | $51.75 | $93.78 | +498% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $8.57 | $8.66 | $10.44 | +0.00% |
| September 2026 | $7.34 | $8.67 | $10.52 | +0.12% |
| October 2026 | $7.55 | $8.98 | $11.01 | +3.55% |
| November 2026 | $7.71 | $9.22 | $11.39 | +2.64% |
| December 2026 | $7.52 | $9.03 | $11.24 | -2.05% |
Click any year to see its month-by-month IMTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The IMTX price prediction for 2026 points to an average of $8.66 (low $8.57, high $11.24) — a potential gain of 0% on today's $8.66. A consolidation phase looks the most probable path here.
In 2027, IMTX is projected to trade between $8.70 and $14.31, averaging $10.86 — a potential gain of +25% from today's $8.66. That is up +25% on the projected 2026 average. Momentum favours further upside here.
Immatics N.V.'s 2028 outlook centres on $12.25, within a $9.56 to $16.73 range. That is up +13% on the projected 2027 average. That marks a +41% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, IMTX could reach as high as $18.88, with a base case around $13.44 and support toward $10.26 — roughly +55% from $8.66. Momentum favours further upside here.
Expect IMTX to range from $10.27 to $19.72 through 2030. The $13.72 average target implies a +58% move from current prices. That is up +2% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The IMTX price prediction for 2031 points to an average of $14.08 (low $10.36, high $20.66) — a potential gain of +63% on today's $8.66. Momentum favours further upside here.
In 2032, IMTX is projected to trade between $11.05 and $22.82, averaging $15.27 — a potential gain of +76% from today's $8.66. That is up +8% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Immatics N.V.'s 2033 outlook centres on $17.76, within a $12.66 to $26.98 range. That is up +16% on the projected 2032 average. That marks a +105% change versus current levels. Momentum favours further upside here.
By 2034, IMTX could reach as high as $32.80, with a base case around $21.26 and support toward $14.93 — roughly +145% from $8.66. Buyers look set to stay in control over this stretch.
Expect IMTX to range from $15.00 to $33.88 through 2035. The $21.65 average target implies a +150% move from current prices. That is up +2% on the projected 2034 average. Momentum favours further upside here.
The IMTX price prediction for 2040 points to an average of $32.49 (low $21.14, high $53.97) — a potential gain of +275% on today's $8.66. Buyers look set to stay in control over this stretch.
In 2050, IMTX is projected to trade between $30.25 and $93.78, averaging $51.75 — a potential gain of +498% from today's $8.66. That is up +59% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in IMTX today (≈ 115.473441 IMTX) could be worth
$5,975.19
+$4,975.19 (+498%) by 2050 · US Dollar
Based on the average projected IMTX price of $51.75 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IMTXwould be worth at today's price.
$1,000 invested in IMTX on Jul 31, 2025 (≈ 155.038764 IMTX) would be worth
$1,342.64
+$342.64 (+34.3%) today · 1.34× · US Dollar
Based on a IMTX entry price of $6.45 vs. today's $8.66.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.08 | $953.74 | -4.6% |
| 1 month ago | $9.85 | $879.19 | -12.1% |
| 3 months ago | $10.79 | $802.59 | -19.7% |
| 6 months ago | $9.99 | $866.87 | -13.3% |
| 1 year ago | $6.45 | $1,342.64 | +34.3% |
| All time (5.0y) ago | $11.93 | $725.9 | -27.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IMTX forecast.
Our base-case forecast reaches $17.00 around 2033.
Implied market cap at $17.00: $2.32B
The multi-year forecast landscape shows a bullish arc, with the 2027 avg price at $11.76 and the 2028 avg at $13.17, rising to a 2030 avg of $15.14 with a 65.1 ROI. The 2040 avg is $36.89 with a 302.3 ROI, and the 2050 avg reaches $59.96 with a 553.9 ROI. The 2030 max is $21.41, the 2040 max is $59.67, and the 2050 max is $105.24, indicating substantial long-term upside despite near-term volatility.
The sentiment is bullish for 2027 onward, but shorter-term movement remains uncertain.
Tap a question to reveal the answer.
In 2030, the forecast average price is $15.14, with a min of $11.49 and a max of $21.41. The forecasted ROI is 65.1 and the sentiment is BULLISH.
Forecasts show a bullish trajectory from 2027 onward, with rising avg prices (e.g., $11.76 in 2027, $15.14 in 2030, up to $59.96 in 2050) and positive ROIs (e.g., 28.2% in 2027, 65.1% in 2030, 553.9% in 2050), though near-term risk remains as indicated by current bearish sentiment.
Yes. The forecast max values include $30.08 in 2033 and higher beyond, with substantial increases continuing to 2050 where the max is $105.24.
The current price is $9.17.
The 30-day range is between $7.85 and $10.71.
Immatics N.V. Community Discussion
0Share your Immatics N.V. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.